Tag: Kiran Mazumdar Shaw
Budget 2025 is reassuring, instils confidence: Kiran Mazumdar Shaw
Chairperson and Managing Director of Biocon welcomed the various initiatives made by the government
Obituary: Bioscience industry pays rich tributes to Ratan Tata
His loss resonates far beyond the corridors of industry, deeply touching the lives of millions he inspired
Kiran Mazumdar Shaw appointed as member of Court of Regents at...
The RCSed’s Court of Regents comprises a group of distinguished and accomplished individuals in their field who provide the College with advice and expertise
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Continuing to expand its global footprint, the company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023
Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%
ABLE’s 20th Anniversary: Realistic policies & regulations critical for bioeconomy to...
Kiran was speaking at the 20th Anniversary Celebration of the Association of Biotechnology Led Enterprises (ABLE) on April 07, 2023. The theme of the event was "India-A Resilient Global Biotech Destination."
BioVoice eMagazine February 2023 Issue 2 Volume 4
Click to Read: February 2023 Edition of BioVoice eMagazine
The Cover Story in the February 2023 issue focuses on the ambitious US$ 300 billion bioeconomy...
G S Krishnan takes charge as new president of ABLE
Krishnan heads a nine-member executive council that was elected last January for a three-year term starting on April 1, 2021.................
New ‘Global Biopharma Resilience Index’ lists 5 major challenges for the...
The global index compiled by global life sciences leader Cytiva, along with the Financial Times’ research arm Longitude has been built on the survey of 1,165 biopharma executives and healthcare policymakers across 20 countries..................
Biocon Biologics to offer its oncology biosimilars in over 30 countries
The company's agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars will enable access to Trastuzumab and Pegfilgrastim in Africa and Asia...................